These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21720)

  • 1. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulphasalazine treatment during breast feeding.
    Järnerot G; Into-Malmberg MB
    Scand J Gastroenterol; 1979; 14(7):869-71. PubMed ID: 44005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulphasalazine-induced leucopenia in a patient with renal dysfunction.
    Teshima D; Hino B; Makino K; Yano T; Itoh Y; Joh Y; Iida M; Oishi R
    J Clin Pharm Ther; 2003 Jun; 28(3):239-42. PubMed ID: 12795783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.
    Azad Khan AK; Truelove SC
    Gut; 1980 Aug; 21(8):706-10. PubMed ID: 6107264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation.
    Esbjörner E; Järnerot G; Wranne L
    Acta Paediatr Scand; 1987 Jan; 76(1):137-42. PubMed ID: 2882643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
    Allgayer H; Kruis W; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route.
    Ashworth M; Arthur M; Turmer AD; Smith PR
    Pharmatherapeutica; 1984; 3(8):551-5. PubMed ID: 6142465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].
    Klugmann HJ; Giehler B; Lohmann D; Schiedewitz W
    Gastroenterol J; 1990; 49(4):160-4. PubMed ID: 1970478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.
    Azad Khan AK; Howes DT; Piris J; Truelove SC
    Gut; 1980 Mar; 21(3):232-40. PubMed ID: 6105118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.
    Astbury C; Taggart AJ; Juby L; Zebouni L; Bird HA
    Ann Rheum Dis; 1990 Aug; 49(8):587-90. PubMed ID: 1975737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine].
    Eitner K; Reinicke C; Hippius M
    Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):282-8. PubMed ID: 6151895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.
    Pullar T; Hunter JA; Capell HA
    Br J Rheumatol; 1985 Aug; 24(3):269-76. PubMed ID: 2861876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 17. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM; Eastwood MA
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
    Eitner K; Hippius M; Reinicke C
    Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.
    Schröder H; Evans DA
    Gut; 1972 Apr; 13(4):278-84. PubMed ID: 4402420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simple and simultaneous determination of sulphapyridine and acetylsulphapyridine in human serum by column-switching high-performance liquid chromatography.
    Teshima D; Hino B; Itoh Y; Oishi R
    J Clin Pharm Ther; 2002 Dec; 27(6):403-8. PubMed ID: 12472979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.